Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review
Authors: Bryant, J., Picot, J., Baxter, L., Levitt, G., Sullivan, I. and Clegg, A.
Journal: European Journal of Cancer
Volume: 43
Issue: 13
Pages: 1959-1966
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.06.012
Abstract:Aim: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer. Methods: Systematic review using a priori methods. Results: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group. Conclusions: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage. Crown Copyright © 2007.
Source: Scopus
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
Authors: Bryant, J., Picot, J., Baxter, L., Levitt, G., Sullivan, I. and Clegg, A.
Journal: Eur J Cancer
Volume: 43
Issue: 13
Pages: 1959-1966
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.06.012
Abstract:AIM: To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer. METHODS: Systematic review using a priori methods. RESULTS: Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group. CONCLUSIONS: The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.
Source: PubMed
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review
Authors: Bryant, J., Picot, J., Baxter, L., Levitt, G., Sullivan, I. and Clegg, A.
Journal: EUROPEAN JOURNAL OF CANCER
Volume: 43
Issue: 13
Pages: 1959-1966
eISSN: 1879-0852
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.06.012
Source: Web of Science (Lite)
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
Authors: Bryant, J., Picot, J., Baxter, L., Levitt, G., Sullivan, I. and Clegg, A.
Journal: European journal of cancer (Oxford, England : 1990)
Volume: 43
Issue: 13
Pages: 1959-1966
eISSN: 1879-0852
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2007.06.012
Abstract:Aim
To evaluate the effectiveness of cardiac markers to quantify anthracycline-induced cardiotoxicity in children with cancer.Methods
Systematic review using a priori methods.Results
Seven studies, all with methodological limitations, were identified. One RCT suggests that cardiac troponin can be used to assess the effectiveness of the cardio-protective agent dexrazoxane. Cohort studies suggest that atrial natriuretic peptide and brain (B-type) natriuretic peptide are elevated in some subgroups of patients compared with healthy children; NT-pro-BNP levels are significantly elevated in children with cardiac dysfunction compared with those without; serum lipid peroxide is higher in children who have received doxorubicin compared with children not receiving doxorubicin; there are no differences in carnitine levels between children treated with doxorubicin and a healthy control group.Conclusions
The limited evidence makes conclusions difficult. Research is needed to fill this important evidence gap and link short-term changes in cardiac markers to longer-term cardiac damage.Source: Europe PubMed Central